The multifaceted role of PUMA in cell death pathways: its therapeutic potential across cancer types
Open Access
- 20 November 2025
- journal article
- review article
- Published by Springer Nature in Cell Communication and Signaling
- Vol. 23 (1) , 499
Abstract
Cell death is a fundamental process essential to all living organisms, with apoptosis serving as one of the most crucial pathways across various stages of life. Dysregulation of apoptosis is closely associated with numerous diseases, particularly cancer. PUMA (p53 upregulated modulator of apoptosis) is a key mediator of apoptotic cell death. It is activated in response to a wide range of internal and external signals. Beyond its established role in apoptosis, PUMA also regulates other forms of cell death, including necroptosis, autophagy, and ferroptosis, underscoring its critical role in cancer cell death, especially during chemotherapy. However, PUMA activation is frequently impaired in many cancers, leading to resistance to cell death and treatment failure. This review highlights recent advancements in understanding the regulation of PUMA expression at multiple levels, including epigenetic, transcriptional, post-transcriptional, and post-translational mechanisms. It also examines the influence of diverse cellular regulators, such as epigenetic modifiers, transcription factors, non-coding RNAs, kinases, and ubiquitin ligases in modulating PUMA activity. Additionally, we discuss PUMA’s role in cancer progression, its impact on the effectiveness of anti-cancer therapies, and its potential as a prognostic biomarker for therapeutic resistance. Finally, we propose critical questions to inspire future research, aiming to deepen the understanding of PUMA regulation and its significance in cancer therapy. The diagram highlights the regulatory network of p53 under stress conditions such as DNA damage, hypoxia, or oncogenic stress. In normal conditions, MDM2 binds to and sequesters p53, leading to its proteasomal degradation. Stress signals activate p53, inducing the pro-apoptotic protein PUMA, which inhibits anti-apoptotic proteins (BCL-2, BCL-XL, and BCL-W), thereby activating the effector proteins BAX and BAK. This activation results in mitochondrial outer membrane permeabilization (MOMP) and cytochrome c (Cyt c) release, triggering caspase activation and apoptosis. Proper apoptosis maintains tissue homeostasis, whereas alterations in this pathway can lead to uncontrolled cell proliferation and cancer.Keywords
This publication has 211 references indexed in Scilit:
- MY11 exerts antitumor effects through activation of the NF-κB/PUMA signaling pathway in breast cancerInvestigational New Drugs, 2022
- The role of P53 up-regulated modulator of apoptosis (PUMA) in ovarian development, cardiovascular and neurodegenerative diseasesApoptosis, 2021
- p53 Up‐regulated Modulator of Apoptosis Induction Mediates Acetaminophen‐Induced Necrosis and Liver Injury in MiceHepatology, 2018
- Phenylbutyl isoselenocyanate induces reactive oxygen species to inhibit androgen receptor and to initiate p53‐mediated apoptosis in LNCaP prostate cancer cellsMolecular Carcinogenesis, 2018
- miR‐125b promotes growth of prostate cancer xenograft tumor through targeting pro‐apoptotic genesThe Prostate, 2010
- Mdm2 inhibition induces apoptosis in p53 deficient human colon cancer cells by activating p73- and E2F1-mediated expression of PUMA and Siva-1Apoptosis, 2010
- 5‐Fluorouracil and its active metabolite FdUMP cause DNA damage in human SW620 colon adenocarcinoma cell lineJournal of Applied Toxicology, 2008
- Contribution of membrane localization to the apoptotic activity of PUMAApoptosis, 2007
- Analysis of the MDM2 antagonist nutlin‐3 in human prostate cancer cellsThe Prostate, 2007
- An androgen-independent androgen receptor function protects from inositol hexakisphosphate toxicity in the PC3/PC3(AR) prostate cancer cell linesThe Prostate, 2006